
Daniel Clark
Related Resources
Related Resources

From Theory to Practice: Evaluating g-values within mint Lesion
Following the FDA’s recent analysis of the growth rate constant (g) as a prognostic marker1, the challenge for many research organizations is…

Bridging the Gap Between RECIST and Survival: Why the FDA’s Analysis of the g Value is a Game-Changer
For decades, oncology trials have relied on RECIST 1.1 to evaluate drug efficacy. However, these categorical "snapshot" evaluations do not always…
